🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

CORONA REMEDIES LIMITED CORONA NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.coronaremedies.com
Company Profile ↓
₹2,068.70
+44.61% 1Y
Mkt Cap₹12,652.19 Cr
P/E68.35
P/B16.82
Div. Yield0.49%
52W High₹2,068.70
52W Low₹1,340.36
Book Value₹122.12
EPS (TTM)₹30.27

Company Overview

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 24.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 29.0%.

Consistent Profit Growth

Net profit has compounded at 29.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 16.6% CAGR over the past five years.

Healthy Margins

Operating margin of 18.3% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.22.

Recent Developments

  • Mar 2026 Revenue of ₹1,401.48 Cr (+17.2% YoY); net profit ₹185.12 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +17.2%, earnings +23.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.6%, profit CAGR 29.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.62%
1 Year:17.23%

Compounded Profit Growth

5 Years:29.66%
1 Year:23.88%

Stock Price Performance

1 Year:+44.61%
6 Months:+42.18%
3 Months:+31.48%
1 Month:+20.11%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 100% of range
₹1,340.36 ₹2,068.70
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)71.38 · Overbought
Price Performance
1M+20.11%
3M+31.48%
6M+42.18%
1Y+44.61%
Valuation vs Sector

P/E of 68.35 is above the sector median of 39.70 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 24.8%.
  • Healthy ROCE of 29.0%.
  • Compounding revenue at 16.6% over 5 years.
  • Profit CAGR of 29.7% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 68.3.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
68.35
Industry PE
39.70
Forward P/E
39.25
PEG Ratio
-
Book Value
₹122.12
Price to Book
16.82
P/S
8.96
EV/EBITDA
43.75
Dividend Yield
0.49%

Growth (CAGR)

Revenue 5Y
16.62%
Profit 5Y
29.66%
Revenue (YoY)
17.23%
Earnings (YoY)
23.88%

Profitability & Returns

ROCE
29.03%
ROE
24.79%
ROA
15.36%
Profit Margin
13.21%
Op Margin
18.29%
Gross Margin
81.38%
EPS (Latest Qtr)
₹7.41
EPS (TTM)
₹30.27

Balance Sheet & Liquidity

Debt/Equity
0.22
Quick Ratio
0.62
Current Ratio
0.96
Debt
₹164.85 Cr
Total Assets
₹1,205.14 Cr
Current Assets
₹348.31 Cr
Working Capital
₹-12.86 Cr

Ownership

Promoter Holding
88.75%
Chg in Prom Hold
19.75%
FII / Inst Holding
7.16%
Chg in FII Hold
-0.16%

Financial Snapshot

Enterprise Value
₹12,652.19 Cr
Total Revenue (TTM)
₹1,401.48 Cr
EBITDA
₹282.86 Cr
Free Cash Flow
₹55.34 Cr
Operating Cash Flow
₹229.48 Cr
Shares Outstanding
₹6.12 Cr
Gross Margin
81.38%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CORONA CORONA REMEDIES LIMITED NSEPHARMA 2,068.70 68.35 ₹12,652.19 Cr 0.49% 29.03% 24.79% 16.62% 29.66%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 314.00 Cr297.69 Cr293.69 Cr346.29 Cr361.00 Cr342.42 Cr353.09 Cr
Cost of Revenue -55.20 Cr56.86 Cr65.78 Cr-60.27 Cr66.24 Cr
Gross Profit -242.49 Cr236.83 Cr280.50 Cr-282.15 Cr286.85 Cr
Operating Expenses 247.00 Cr182.76 Cr192.65 Cr219.45 Cr283.00 Cr208.44 Cr235.12 Cr
Operating Income 58.00 Cr59.73 Cr44.18 Cr61.05 Cr69.00 Cr73.71 Cr51.73 Cr
EBITDA 67.00 Cr70.36 Cr55.85 Cr71.00 Cr78.00 Cr66.32 Cr66.41 Cr
Interest Expense 3.00 Cr2.39 Cr2.20 Cr1.39 Cr2.00 Cr1.66 Cr1.38 Cr
Pretax Income 57.00 Cr58.28 Cr43.61 Cr60.69 Cr70.00 Cr55.21 Cr54.74 Cr
Tax Provision 14.25 Cr13.33 Cr12.06 Cr14.50 Cr17.50 Cr13.94 Cr9.41 Cr
Net Income 43.00 Cr44.95 Cr31.55 Cr46.20 Cr52.00 Cr41.27 Cr45.33 Cr
Diluted EPS 7.037.355.167.558.556.757.41

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 883.53 Cr1,013.68 Cr1,195.51 Cr1,401.48 Cr
Cost of Revenue 210.95 Cr226.83 Cr236.52 Cr260.94 Cr
Gross Profit 672.57 Cr786.85 Cr958.99 Cr1,140.54 Cr
Operating Expenses 564.49 Cr659.02 Cr755.39 Cr884.25 Cr
Operating Income 108.09 Cr127.83 Cr203.60 Cr256.29 Cr
EBITDA 133.38 Cr158.25 Cr243.73 Cr282.86 Cr
Interest Expense 2.38 Cr11.49 Cr8.04 Cr4.57 Cr
Pretax Income 110.89 Cr118.48 Cr198.53 Cr240.42 Cr
Tax Provision 25.96 Cr27.98 Cr49.10 Cr55.30 Cr
Net Income 84.93 Cr90.50 Cr149.43 Cr185.12 Cr
Diluted EPS 13.8914.8024.4330.27

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 595.02 Cr830.58 Cr929.86 Cr1,205.14 Cr
Current Assets 291.49 Cr289.92 Cr338.87 Cr348.31 Cr
Cash & Equivalents 14.49 Cr3.16 Cr3.22 Cr1.83 Cr
Inventory 105.40 Cr98.34 Cr129.48 Cr125.00 Cr
Receivables 86.99 Cr99.93 Cr118.29 Cr145.55 Cr
Total Liabilities 186.50 Cr350.17 Cr323.52 Cr458.28 Cr
Current Liabilities 137.37 Cr224.19 Cr239.59 Cr361.17 Cr
Long Term Debt 067.00 Cr16.00 Cr0
Total Debt 27.96 Cr158.96 Cr86.24 Cr164.85 Cr
Total Equity 408.52 Cr480.41 Cr606.34 Cr746.86 Cr
Shares Outstanding 6.12 Cr6.12 Cr6.12 Cr6.12 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 102.70 Cr156.76 Cr190.49 Cr229.48 Cr
Investing Cash Flow -50.24 Cr-266.64 Cr-83.86 Cr-256.15 Cr
Financing Cash Flow -44.75 Cr98.55 Cr-106.57 Cr25.28 Cr
Capital Expenditure -94.76 Cr-286.34 Cr-91.66 Cr-174.14 Cr
Free Cash Flow 7.94 Cr-129.58 Cr98.83 Cr55.34 Cr
Net Change in Cash 7.71 Cr-11.34 Cr6.00 L-1.39 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % 76.1%77.6%80.2%81.4%
Operating Margin % 12.2%12.6%17.0%18.3%
Net Margin % 9.6%8.9%12.5%13.2%
ROE % 20.8%18.8%24.6%24.8%
ROCE % 23.6%21.1%29.5%30.4%

Shareholding Pattern

Insiders
88.75%
Institutions
7.16%
Public Float
63.70%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CORONA

Google News Mon, 13 Jul 2026

6 Best Vaccine Stocks for 2026 and How to Invest - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNR1RSbmdma2Z6NGJydEc0cFUzejZiX3lGZzhWZmNuNGNJM2cwQlJpSXlzQlAzejZmVnFSTzRla3NoVkMtN04zQ0NjUk1uTHlfTFJSMG8zbkRTQjY2eVNCUXgwRXZIUVFpOGxHZjhXMFJHaXNEMk1ZeTAtTF8wcmg2TlQ3czVNdDRjRnRUbX…

Google News Mon, 29 Jun 2026

This Modelo and Corona Beer Maker Reports Earnings Tuesday. Here's How Much Its Stock Could Move - Investopedia

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPRC0yd2dDZTNfeEJKVGE3UEFncXJ2cDE3SXRXWndfcjh5Q2puZ05FVGF4QkwydmM4MW1GRldkLThBSTNOcXJjR2owaklNY3ZneHlPbWloSVpxZk9FdjU1ejBzLUdSTERMUFZJdTlCZFIxcm9xS2FvV1pVaGVxSHk0WThMZV9DdlVLVUp0cU…

Google News ue, 07 Apr 2026

Corona brewer’s stock has rallied ahead of earnings amid signs of improving beer sales - MarketWatch

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQdVF1THhzOW1oTXZ0V0tpUEU4TldIZUxQWjZLNWVpTkZUT3NYTHd2aktVZWpuTEZTQjYtUlJKc2FWX25fbk1STGRxUXgyR0tQMVJSZjUzb0FrcmJaRDMzZDBLMl80WDhxTGxhTnpIeEZkOEk3WlRuVEFQXzdhdjFzSDNiWm9GTEk3Nk9NUk…

Google News Wed, 03 Dec 2025

Why Corona and Modelo sales are hurt by immigration crackdown | CNN Business - CNN

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNbjVvVkFGUS14ZVFoWi1qV21OcHdtcDhHU3ozeVRodElweEhzNFA0RHlOXzRjVDgtWlREQ252ZzFhY0ktSDMxNUZFajB6U3locWltM2tSQ0lxZ3U4NUJNaXUwVHdDQm5DZkNPZ2tlTXVYd0hoZDRxakZxQTcwVFoyeElqbzhmVjhtMzl3X3…

Google News Sun, 16 Nov 2025

Motley Fool: Brewing Profits - The Spokesman-Review

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9HUlU0Q0tza25VWURkbkhTbFJkWjB5X0xQTDFZVUU1RVZTcVdySHFyVE5mSllDNVhOV2pPVUhQbWRUcnpUNnpBanlyLWNlWG1wVUpmU1ZvYXF0eHNKeE5rc0dVcDltZ25xNS1jejRSamFiRFZiSE1sMWVsbTZJODA?oc=5" target="_bla…

Google News ue, 03 Mar 2026

Effect of coronavirus on major global stock indices 2020-2021 - Statista

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQUno0U2NKLTVKS0c0VkZTOGdyZks0MFpvMTZZTm1DTGZadl93Wkp1N3h5ZEpwUU95Sm5aSGhuWHl3eUwxTkFWcmtjUUlLeVZiSU1KNUF2dXFScDNXTnFfbEpNRHpaUENLQTVua2d4WnNHcUZSZVV4SWFBcWR6Zm1Ham9SYTFrelV3UFFUNn…

CORONA — Frequently Asked Questions

What is the current share price of CORONA REMEDIES LIMITED (CORONA)?

As of 2026-07-16 05:21 IST, CORONA REMEDIES LIMITED (CORONA) trades at ₹2,068.70 on NSE. Its 52-week range is ₹1,340.36 to ₹2,068.70.

What is the market capitalisation of CORONA?

CORONA REMEDIES LIMITED (CORONA) has a market capitalisation of ₹12,652.19 Cr on NSE.

What is the P/E ratio of CORONA?

CORONA trades at a trailing price-to-earnings (P/E) ratio of 68.35. The industry average P/E is 39.70. Its price-to-book (P/B) ratio is 16.82.

Does CORONA pay a dividend?

CORONA REMEDIES LIMITED (CORONA) currently offers a dividend yield of 0.49%.

What is the return on equity (ROE) of CORONA?

CORONA has a return on equity (ROE) of 24.79%. Its return on capital employed (ROCE) is 29.03%.

Is CORONA a good stock to buy?

This page provides a data-driven analysis of CORONA REMEDIES LIMITED (CORONA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space